Abzena expands deal with University College London for making Magacizumab

Abzena has signed a deal with University College London (UCL) to manufacture Magacizumab, an antibody created with its ‘Abzena inside’ Composite Human Antibody technology.

This isn’t the first agreement with UCL, as earlier, Abzena had conducted the antibody humanization and developed the manufacturing cell line for Magacizumab. For this deal Abzena will manufacture Magacizumab at its biomanufacturing facility in San Diego, USA.

As per the previous agreement with UCL, Abzena will get a milestone payment during clinical development of Magacizumab.

Magacizumab is an ‘Abzena inside’ product developed by the UCL Institute of Ophthalmology for the treatment of neovascular (or ‘wet’) age-related macular degeneration (AMD). This is a condition affecting older people that can lead to loss of vision due to abnormal blood vessel growth.